SOST and osteoporosis: Translating these findings into therapeutic concepts, it is most likely that the recently approved sclerostin antibody romosozumab [6, 97] is especially effective in disuse osteoporosis, but the efficacy of romosozumab in association with conditions of disuse osteoporosis has to be investigated in future clinical studies.